|
Multiple Myeloma
|
0.420 |
GeneticVariation
|
disease |
GWASCAT |
Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk.
|
23955597 |
2013 |
|
Multiple Myeloma
|
0.420 |
GeneticVariation
|
disease |
GWASCAT |
The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma.
|
23502783 |
2013 |
|
Multiple Myeloma
|
0.420 |
GeneticVariation
|
disease |
GWASDB |
Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk.
|
23955597 |
2013 |
|
Multiple Myeloma
|
0.420 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide association study identifies multiple susceptibility loci for multiple myeloma.
|
27363682 |
2016 |
|
Multiple Myeloma
|
0.420 |
GeneticVariation
|
disease |
BEFREE |
SNPs correlated with the index signal in 22q13.1 cluster around the promoter and enhancer regions of CBX7 CONCLUSIONS: We found that reported multiple myeloma susceptibility regions contain risk variants important across populations, supporting the use of multiple racial/ethnic groups with different underlying genetic architecture to enhance the localization and identification of putatively functional alleles.
|
27587788 |
2016 |
|
Red Blood Cell Count measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
White Blood Cell Count procedure
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common Complex Disease.
|
27863252 |
2016 |
|
Lymphocyte Count measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common Complex Disease.
|
27863252 |
2016 |
|
Primary amyloidosis
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide association study of immunoglobulin light chain amyloidosis in three patient cohorts: comparison with myeloma.
|
28025584 |
2017 |
|
Mammary Neoplasms
|
0.030 |
GeneticVariation
|
group |
BEFREE |
Expression of ANRIL-Polycomb Complexes-CDKN2A/B/ARF Genes in Breast Tumors: Identification of a Two-Gene (EZH2/CBX7) Signature with Independent Prognostic Value.
|
27102007 |
2016 |
|
Lymphoma, Follicular
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
These data identify CBX7 as a chromobox protein causally linked to cancer development and may help explain the low frequency of INK4a/ARF mutations observed in human follicular lymphoma.
|
17374722 |
2007 |
|
Multiple Myeloma
|
0.420 |
Biomarker
|
disease |
CTD_human |
Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk.
|
23955597 |
2013 |
|
Multiple Myeloma
|
0.420 |
Biomarker
|
disease |
BEFREE |
We show that PTC-209 reduces the viability of MM cells via induction of apoptosis and reveal that the anti-MM actions of PTC-209 are mediated by on-target effects i.e. downregulation of BMI-1 protein and the associated repressive histone mark H2AK119ub, leaving other PRC1 subunits such as CBX-7 and the catalytic subunit RING1B unaffected.
|
29262596 |
2017 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Among the identified CBX7-interacting proteins we focused our attention on the Protein Arginine Methyltransferase 1 (PRMT1) whose critical role in epithelial-mesenchymal transition (EMT), cancer cell migration and invasion has been already reported.
|
30826432 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These data identify CBX7 as a chromobox protein causally linked to cancer development and may help explain the low frequency of INK4a/ARF mutations observed in human follicular lymphoma.
|
17374722 |
2007 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Polycomb protein chromobox homolog 7 (CBX7) is involved in several biologic processes including stem cell regulation and cancer development, but its roles in breast cancer remain unknown.
|
25351982 |
2015 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Polycomb repressor complex 1-chromobox7 (CBX7) has emerged as a key regulator in several cellular processes including stem cell self-renewal and cancer cell proliferation.
|
31630421 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These data suggest that CBX7 is a tumor suppressor and that its loss plays a key role in the pathogenesis of cancer.
|
22214847 |
2012 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The role of CBX7 in most types of cancer is still not clear.
|
20723236 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These data suggest that CBX7 is a tumor suppressor and that its loss plays a key role in the pathogenesis of cancer.
|
22214847 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These findings suggest CBX7 is an important tumor suppressor that negatively modulates PTEN/Akt signaling during pancreatic tumorigenesis.
|
28030829 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CBX7, a member of the Polycomb-group proteins, plays a significant role in normal and cancerous tissues and has been defined as a tumor suppressor in thyroid, breast and pancreatic cancers.
|
28388562 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our findings suggest that CBX7 might be a tumor suppressor and could be a potential target in cervical cancer.
|
31709304 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This role is supported from the development of benign and malignant neoplasias in Cbx7 null mice.
|
28259135 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken together, these findings indicate that CBX7-mediated epigenetic induction of DKK-1 is crucial for the inhibition of breast tumorigenicity, suggesting that CBX7 could be a potential tumor suppressor in human breast cancer.
|
25351982 |
2015 |